Disclaimer The following content is for informational and educational purposes only and does not constitute financial or investment advice. English Version Viking Therapeutics Research 1. Key Metrics & Timeline Summary * Cash Runway: Funded through 2028. As of mid-2026, Viking holds approximately $502 million in cash and short-term investments
Why I Focus on Biopharmaceutical Investment Research 1. Evading the "Unicorn Bubble": Embracing Early Public Market Access In an era where major tech and AI unicorns are heavily monopolized by private equity giants (VC/PE) in primary markets—often overinflating valuations decades into the future before IPO—secondary
Disclaimer: This document is provided solely for academic and industry research exchanges and does not constitute any investment advice, medical diagnosis, or decision-making basis. Markets carry risks; investments require caution. English Version BioNTech (BNTX) Core Investment Logic & Value Reconstruction Analysis 1. Revenue Structure: End of COVID-19 &
Disclaimer: This document is provided for informational and academic research purposes only and does not constitute financial, legal, or investment advice. English Version Research Report: Oscar Health (OSCR) — S-Curve Penetration Path, Policy Valuation Option, and Death-Spiral Tail Risk Executive Summary Oscar Health (NYSE: OSCR), a technology-driven health
BridgeBio Pharma (BBIO): Commercial Breakthrough, S-Curve Trajectory, and Valuation Analysis Executive Summary BridgeBio Pharma (NASDAQ: BBIO) has successfully transitioned from an early-stage biopharma developer into a commercial-stage biopharmaceutical leader specializing in rare diseases. Driving this transition is its core product, Attruby® (acoramidis), targeting transthyretin amyloid cardiomyopathy (ATTR-
English Version Revenue Structure and S-Curve Penetration Analysis of Neurocrine Biosciences, Inc. Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is currently at a critical transition point, evolving from a single-blockbuster-driven company into a multi-pillar Central Nervous System (CNS) and endocrine platform. 1. Revenue Structure Analysis Based on H1
English Version Guardant Health: Multi-Engine Growth and the $100 Billion Market Cap Potential Guardant Health (NASDAQ: GH) is undergoing a major commercial inflection, transitioning from a specialized provider of late-stage therapy selection tests into a comprehensive, full-cycle precision oncology platform. Driven by robust clinical adoption, landmark regulatory
English Version Insmed Incorporated (NASDAQ: INSM) has successfully transformed from a research-stage biotechnology firm into a fully integrated commercial biopharmaceutical company with a potential peak revenue pipeline exceeding $14 billion. Revenue Structure and S-Curve Positioning The company's commercial revenue structure has transitioned into a dual-engine
English Version Axsome Therapeutics (NASDAQ: AXSM): Revenue Structure, S-Curve Trajectory, Market Potential, and Valuation Analysis In the second quarter of 2026, Axsome Therapeutics achieved a total net product revenue of $218.4 million, representing a 46% year-over-year growth. The company’s revenue structure is driven by three
Synthesis: Benefits, Challenges, and Economics of Individualized mRNA Cancer Vaccines Think of modern cancer treatment as a coordinated strategy: targeted pills, ADCs, and chemotherapy act as frontline heavy artillery that quickly shrinks large tumors, while the body's immune system acts as the internal security defense. Personalized mRNA cancer
The Next Era of US Biopharma: Modality Shifts, Late-Stage Focus, and Supply Chain Realignment Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. I. Evolution of the Biopharma Landscape & Core US Equity
Disclaimer: This article is provided strictly for analytical, research, and educational purposes and does not constitute financial, investment, or medical advice. Beyond the Spreadsheet: Why Wall Street’s Skepticism Misjudges the Paradigm Shift of Moderna’s mRNA Cancer Vaccine On August 23, 2026, The Wall Street Journal published an analysis